FK 409

Drug Profile

FK 409

Alternative Names: FR 900409; FR 900411

Latest Information Update: 17 Apr 2002

Price : $50

At a glance

  • Originator Fujisawa; Nonindustrial source
  • Class Antiplatelets; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Heart transplant rejection; Lung transplant rejection; Peptic ulcer; Renal failure
  • Discontinued Angina pectoris; Heart failure; Hypertension; Thrombosis

Most Recent Events

  • 24 May 2000 Preclinical development for Heart transplant rejection in Japan (Unknown route)
  • 13 Apr 2000 An animal study was added to the pharmacodynamic section of transplant rejection
  • 11 Apr 2000 An animal study has been added to the pharmacodynamics section of transplant rejection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top